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Abstract
Background: Henoch-Schönlein purpura (HSP) is the most common vasculitis in childhood; nevertheless, its
etiology and pathogenesis remain unknown despite the fact that a variety of factors, mainly infectious agents,
drugs and vaccines have been suggested as triggers for the disease. The aim of this study was to estimate the
association of HSP with drug and vaccine administration in a pediatric population.
Methods: An active surveillance on drug and vaccine safety in children is ongoing in 11 clinical centers in Italy. All
children hospitalized through the local Paediatric Emergency Department for selected acute clinical conditions of
interest were enrolled in the study. Data on drug and vaccine use in children before the onset of symptoms
leading to hospitalization were collected by parents interview. A case-control design was applied for risk estimates:
exposure in children with HSP, included as cases, was compared with similar exposure in children with gastroduodenal
lesions, enrolled as controls. HSP cases were validated according to EULAR/PRINTO/PRES criteria. Validation was
conducted retrieving data from individual patient clinical record.
Results: During the study period (November 1999–April 2013), 288 cases and 617 controls were included. No increased
risk of HSP was estimated for any drug. Among vaccines, measles-mumps-rubella (MMR) vaccine showed an increased
risk of HSP (OR 3.4; 95 % CI 1.2–10.0).
Conclusions: This study provides further evidence on the possible role of MMR vaccine in HSP occurrence.
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Background
Henoch-Schönlein purpura (HSP), recently renamed as
IgA vasculitis, is a systemic leukocytoplastic vasculitis
characterized by IgA1 dominant immune deposits [1, 2].
HSP is the most common vasculitis in childhood with
an incidence of 10–20 cases per 100,000 in children
under 17 years with a peak incidence of 70 cases per
100,000 in the 4–6 year age group [1, 2].
According to the last endorsed criteria by the EULAR/
PINTO/PRES and American College of Rheumatology
(ACR) the HSP diagnosis requires the presence of the
palpable purpura and at least one of the following: arth-
ritis or arthralgia, diffuse abdominal pain, renal involve-
ment with haematuria and/or proteinuria or any biopsy
showing predominant IgA deposition [2–4].
The HSP has an excellent outcome in the majority of
cases with a complete remission in four weeks, about
20–55 % of children have a renal involvement but only
<1 % develop an end-stage kidney disease. The patho-
genesis of this vasculitis should be attributed to the IgA1
containing immune complexes deposition on the small
vessels causing the damage and consequently all clinical
manifestations. Although HSP clinical manifestations
and prognosis are well-defined, the etiology of the dis-
ease remains unknown. It is clear that genetics and an
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abnormal immune response play a pivotal role in the
pathogenesis of HSP [2, 5–7].
However a combination of additional factors has been
suggested to trigger the disease, as infectious agents,
drugs and vaccinations [8–14].
HSP following drug and vaccine administration has
been described in case reports and in a small number of
observational studies conducted during vaccination cam-
paigns [15–34].
Since 1999 the Italian National Institute of Health is
coordinating an active surveillance on the role of drugs
and vaccines in the occurrence of specific clinical condi-
tions responsible for hospitalization of pediatric patients.
Non-infectious muco-cutaneous diseases are among the
clinical conditions of interest and the present study fo-
cused on HSP cases to estimate their association with
drug and vaccine use in the pediatric population.
Methods
Setting and study population
The Italian multicenter study on drug and vaccine safety
in children involved 11 Italian Pediatric hospitals/wards
spread throughout the country (Treviso, Padua, Naples,
Genoa, Turin, Florence, Perugia, Palermo, Messina and
Rome, with two centers).
Were enrolled in the study all children (age >
1 month and ≤ 18 years) hospitalized through the
Emergency Departments (ED) for the following acute
conditions: thrombocytopenia (platelet count <100 ×
103/L); acute non-infectious, non-febrile neurological
disorders; endoscopically confirmed gastroduodenal le-
sions and/or clinically defined haematemesis and melena
and non-infectious muco-cutaneous diseases and vascu-
litis. Exclusion criteria were represented by a concomitant
diagnosis of cancer or immunodeficiency.
Data collection
During hospital admission of the child, a trained
pharmacist/physician interviewed parents to collect
demographic and clinical information using a structured
questionnaire.
Data on drug exposure in a time window of 3 weeks
preceding hospitalization, extended to 12 weeks for vac-
cines, were collected.
For all children the inclusion in the study was based
on the diagnosis retrieved from the ED records inde-
pendently of drug and vaccine exposure.
Ethical approval and consent to participate
According to the Italian regulation, retrospective obser-
vational studies are only required to be notified to eth-
ical committees. The study protocol was notified to the
ethical committee of each participating Center. Before
parents interview, a written informed consent to use
data for research purposes was obtained.
Definition of cases and controls
All children hospitalized with a diagnosis of HSP at ad-
mission were included as cases. Discharge diagnosis was
retrieved from clinical records and validated by clini-
cians, according to EULAR/PRINTO/PRES criteria for
classification of HSP [3, 4]. Validation was conducted re-
trieving data from individual patient clinical record,
blinded with respect to drug and vaccine exposure. Only
validated cases were analyzed.
Children hospitalized for gastroduodenal lesions were
considered as appropriate controls, since they represent
an acute condition admitted through the EDs in the
same clinical centers in which cases were identified.
Statistical analysis
Descriptive analyses of demographic characteristics of
case and control patients, drug and vaccine exposure
were performed. Categorical variables, presented as
numbers and percentages, were compared using the Chi
Square test, while continuous variables, reported as me-
dian and range were compared using the Mann-Whitney
U test. All tests were two sided and significance was set
at p < 0.05.
A case-control study design was applied to compare
drug and vaccine exposure in children with HSP, (cases)
and children with gastroduodenal lesions (controls). A
multiple logistic regression model was used to estimate
adjusted Odds Ratios (ORs) and related 95 % confidence
interval (CI). Age and concomitant use of any other drug
were considered potential confounding factors. Statis-
tical analysis was performed by means of IBM® SPSS®
statistics (version 22).
Results
During the period November 1999–April 2013, a total of
2600 patients with a diagnosis of muco-cutaneous dis-
ease were enrolled in the study. Among these hospital-
ized pediatric patients, 366 were diagnosed as HSP at
the ED. For the validation phase of HSP cases, clinical
records of 298 children (81 % of total), were retrieved.
Only 10 cases did not fulfill the diagnostic criteria for
the disease as described in the score according to
EULAR/PRINTO/PRES criteria (Fig. 1). In all the
remaining 288 HSP validated cases, a palpable purpura
was present, accompanied by arthralgia/arthritis in 85 %;
abdominal involvement with abdominal pain, melena,
intussusception in 65 %; renal involvement with haema-
turia, proteinuria in 35 % and scrotal swelling in 7 %. In
the same period 617 children were enrolled with gastro-
duodenal lesions. Haematemesis and melena accounted
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for most of gastrointestinal diagnosis. Characteristics of
cases and controls are reported in Table 1.
Median duration of hospitalization was similar in both
groups, even if the statistical test was statistically signifi-
cant, indicating difference in the distribution around the
median. Controls were significantly younger than cases
(6 vs. 3 years). Drug and vaccine exposure resulted sig-
nificantly higher in controls.
Crude and adjusted ORs were estimated for each
drug considering at least five exposed cases. No sig-
nificant increased risk was estimated for any drug
(Table 2).
The risk estimated for HSP within 12 weeks after vac-
cination resulted higher, more than 3 times, for MMR
vaccines with an OR of 3.4 (95 % CI 1.2–10.0) while no
significant increased risks were observed for diphtheria,
tetanus, acellular pertussis (DTaP) and any vaccine
(Table 3).
Discussion
Despite the fact that HSP is the commonest, mainly self-
limiting, systemic vasculitis in childhood, its etiology
and pathogenesis remain still to be fully understood.
Many chemical and infectious triggers have been rec-
ognized for the HSP typical vascular IgA deposition,
including drugs and vaccines beside the role played
by immunological, genetic and environmental factors
[13, 14, 35]. Furthermore no risk estimates for HSP
and drug or vaccine exposure have been published.
This study aimed to investigate the association and
the potential role of drugs and vaccines in the occur-
rence of HSP in a pediatric population.
HSP diagnosis is difficult at admission since there are
no disease-specific laboratory abnormalities, neither
signs and symptoms, histopathological findings are
needed to properly identify HSP cases. Only HSP vali-
dated cases, according to the EULAR/PRINTO/PRES
criteria, were considered for the statistical analyses. The
causality assessment on each HSP case was not per-
formed and was beyond the scope of this study.
The clinical presentation of the 288 validated cases
confirmed what previously reported as main clinical fea-
tures for HSP [2]. In addition to the palpable purpura,
hallmark of the disease, articular and abdominal involve-
ment has been described in the majority of the patients
whereas renal and genital involvement were less fre-
quent. According to the literature, the median age of
HSP cases was in accordance with that reported else-
where (4-6 years), so as the equal distribution among
male and female subjects [1, 2, 5].
The characteristics of the 68 cases in which clinical re-
cords were not retrieved were similar for age, gender,
previous febrile infections, drug and/or vaccine exposure
to the retrieved cases thus excluding a possibility for se-
lection bias.
Table 1 Characteristics of the study population
Cases Controlsa
Number 288 617
Median age (range) 6y (2 m–18y) 3y (1 m–18y) p < 0.001
% Females 48 45 p = 0.8
Median length of hospital
stay (range, days)
4 (1–31) 3 (1–37) p < 0.001
Median interval from
drug/vaccine to symptom
onset (range, days)
2 (0–60) 0 (0–90) p < 0.001
Children exposed to
drugs: N (%)
175 (61) 435 (71) p < 0.08
Children exposed to
vaccines: N (%)
21 (7) 68 (11) p = 0.08
agastroduodenal lesions
Table 2 Odds ratio of developing HSP associated with drugs
Drugs Cases (288) Controlsa
(617)
Crude OR
(95 % CI)
Adjusted ORb
(95 % CI)
Antibiotics 65 156 0.7 (0.5–1.0) 1.0 (0.7–1.5)
Penicillins 38 72 0.9 (0.5–1.4) 1.3 (0.8–2.0)
Cephalosporin 21 49 0.7 (0.4–1.3) 1.1 (0.7–2.0)
Macrolides 7 37 0.3 (0.1–0.7) 0.4 (0.2–0.9)
NSAIDs 47 101 0.8 (0.5–1.2) 0.9 (0.6–1.4)
Niflumic acid 12 14 1.4 (0.6–3.3) 1.9 (0.6–1.4)
Ibuprofen 29 61 0.8 (0.5–1.3) 1.1 (0.7–1.7)
Paracetamol 62 163 0.6 (0.4–0.9) 0.8 (0.6–1.1)
Corticosteroids 31 104 0.5 (0.3–0.8) 0.8 (0.5–1.3)
Non users 113 182
agastroduodenal lesions bOR adjusted by age and concomitant use of other drug
366 registered
288 validated
68 not retrieved 
for validation
298 retrieved
10 not validated
Fig. 1 Enrollment, retrieving and validation process of HSP patients
Table 3 Odds ratio of developing HSP associated with vaccines
Vaccine Cases (288) Controlsa (617) Crude OR
(95 % CI)
Adjusted ORb
(95 % CI)
MMR 8 (2.8 %) 6 (1 %) 2.7 (0.8–9.7) 3.4 (1.2–10.0)
DTaP 4 (1.4) 6 (1 %) 1.4 (0.3–6.1) 2.0 (0.5–7.7)
Any vaccine 21 (7.3 %) 68 (11 %) 0.6 (0.4–1.1) 0.9 (0.5–1.4)
agastroduodenal lesions bOR adjusted by age
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Children hospitalized for gastroduodenal lesions have
been considered as a suitable control group for HSP pa-
tients. In this study both cases and controls have been
identified through EDs for an acute condition in the same
clinical centers and, consequently, drug and vaccine ex-
posure, preceding symptoms causing hospitalization, have
been ascertained with the same procedure by interviewing
parents during their child hospitalization.
Our results provide no evidence of an increased risk of
developing HSP associated with any of the drugs
considered.
A three-fold increase risk of developing HSP associ-
ated with MMR vaccine was estimated.
Prospective studies conducted during MMR vaccin-
ation campaign reported HSP cases following vaccine
administration [28–30]. Within the Italian Pharmacov-
igilance System some spontaneous reports of HSP were
reported after MMR vaccine [36]. During the Chinese
MMR vaccination campaign, 30 severe adverse reactions
out of 14.3 millions of administered doses were reported;
among these, 28 cases were diagnosed as HSP with an
estimated incidence of 2.1 per million/doses [30]. Our
study confirmed these observational data, providing a
risk estimate for this association.
Given the case-control design we could not calculate
any incidence estimate.
This article confirms that HSP is a rare condition (288
children hospitalized in 14 years). Furthermore, the vac-
cinated cases were only 8, suggesting a very low absolute
risk of the condition in children vaccinated with MMR
vaccine. Thus, the benefit/risk profile of MMR vaccine is
not affected by our results, being MMR vaccination an
effective and safe tool against serious diseases in
childhood.
With regard to drugs an association of gastroduodenal
lesions with NSAIDs has been previously highlighted
[37]. This could have lead to an underestimation of the
results obtained in the present study concerning the role
of NSAIDs in the development of HSP. It was beyond
the objective of the present study to investigate the
pathogenetic role of drugs and vaccines in the HSP
occurrence.
Conclusions
The association between MMR vaccination and HSP
confirms previous published findings and adds a risk es-
timate. Further studies are needed to increase our un-
derstanding of the role of drugs and vaccines in the
etiology of HSP, a disease with important effects on
health of children for its potential, though rare, chronic
outcomes.
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